Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1992 Jul;216(1):55–59. doi: 10.1097/00000658-199207000-00008

Prognostic value of CA 19.9 levels in colorectal cancer.

X Filella 1, R Molina 1, J J Grau 1, J M Piqué 1, J C Garcia-Valdecasas 1, E Astudillo 1, A Biete 1, J M Bordas 1, A Novell 1, E Campo 1, et al.
PMCID: PMC1242546  PMID: 1632702

Abstract

Pretreatment serum levels of carbohydrate antigen 19.9 (CA 19.9) and carcinoembryonic antigen were measured in 293 patients with colorectal cancer. Carbohydrate antigen 19.9 was above the cut-off limit of 37 U/mL in 35% of patients. Carbohydrate antigen 19.9 sensitivity was related to tumor stage. Carcinoembryonic antigen was above the cut-off level of 3.5 ng/mL in 61% of patients, and the simultaneous use of two markers increased sensitivity to 66%. The main use of pretreatment levels of CA 19.9 in locoregional cancer is in prognosis. Carbohydrate antigen 19.9 provided more prognostic information than that obtained by conventional staging methods. In patients with Dukes' C tumors, additional information was obtained for allocation of these patients into groups at low or high risk of recurrence. Prognostic significance of carcinoembryonic antigen was not independent of Dukes' classification.

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASTLER V. B., COLLER F. A. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg. 1954 Jun;139(6):846–852. doi: 10.1097/00000658-195406000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Babaian R. J., Orlando R. P. Elevated prostatic acid phosphatase: a prognostic factor for stage C adenocarcinoma of the prostate. J Urol. 1986 Nov;136(5):1035–1037. doi: 10.1016/s0022-5347(17)45199-8. [DOI] [PubMed] [Google Scholar]
  3. Del Villano B. C., Brennan S., Brock P., Bucher C., Liu V., McClure M., Rake B., Space S., Westrick B., Schoemaker H. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983 Mar;29(3):549–552. [PubMed] [Google Scholar]
  4. DelVillano B. C., Zurawski V. R., Jr The carbohydrate antigenic determinant 19-9 (CA 19-9): a monoclonal antibody defined tumor marker. Lab Res Methods Biol Med. 1983;8:269–282. [PubMed] [Google Scholar]
  5. Filella X., Molina R., Bedini J. L., Jo J., Joseph J., Ballesta A. M. Clinical usefulness of CEA as tumor marker in patients with colorectal cancer. J Nucl Med Allied Sci. 1990 Oct-Dec;34(4 Suppl):107–110. [PubMed] [Google Scholar]
  6. Koprowski H., Steplewski Z., Mitchell K., Herlyn M., Herlyn D., Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979 Nov;5(6):957–971. doi: 10.1007/BF01542654. [DOI] [PubMed] [Google Scholar]
  7. Kuusela P., Jalanko H., Roberts P., Sipponen P., Mecklin J. P., Pitkänen R., Mäkelä O. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer. 1984 Feb;49(2):135–139. doi: 10.1038/bjc.1984.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Magnani J. L., Brockhaus M., Smith D. F., Ginsburg V., Blaszczyk M., Mitchell K. F., Steplewski Z., Koprowski H. A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science. 1981 Apr 3;212(4490):55–56. doi: 10.1126/science.7209516. [DOI] [PubMed] [Google Scholar]
  9. Magnani J. L., Nilsson B., Brockhaus M., Zopf D., Steplewski Z., Koprowski H., Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982 Dec 10;257(23):14365–14369. [PubMed] [Google Scholar]
  10. Martin E. W., Jr, Minton J. P., Carey L. C. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg. 1985 Sep;202(3):310–317. doi: 10.1097/00000658-198509000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Molina R., Filella X., Mengual P., Prats M., Zanon G., Daniels M., Ballesta A. M. MCA in patients with breast cancer: correlation with CEA and CA15-3. Int J Biol Markers. 1990 Jan-Mar;5(1):14–21. [PubMed] [Google Scholar]
  12. Norton J. A. Carcinoembryonic antigen. New applications for an old marker. Ann Surg. 1991 Feb;213(2):95–97. doi: 10.1097/00000658-199102000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sugarbaker P. H. Carcinoma of the colon--prognosis and operative choice. Curr Probl Surg. 1981 Dec;18(12):753–802. doi: 10.1016/s0011-3840(81)80010-x. [DOI] [PubMed] [Google Scholar]
  14. Szymendera J. J., Nowacki M. P., Kozłowicz-Gudzińska I., Kowalska M. Value of serum levels of carcinoembryonic antigen, CEA, and gastrointestinal cancer antigen, GICA or CA 19-9, for preoperative staging and postoperative monitoring of patients with colorectal carcinoma. Dis Colon Rectum. 1985 Dec;28(12):895–899. doi: 10.1007/BF02554298. [DOI] [PubMed] [Google Scholar]
  15. Wanebo H. J. Are carcinoembryonic antigen levels of value in the curative management of colorectal cancer? Surgery. 1981 Mar;89(3):290–295. [PubMed] [Google Scholar]
  16. Wanebo H. J., Rao B., Pinsky C. M., Hoffman R. G., Stearns M., Schwartz M. K., Oettgen H. F. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978 Aug 31;299(9):448–451. doi: 10.1056/NEJM197808312990904. [DOI] [PubMed] [Google Scholar]
  17. von Kleist S. The clinical value of the tumor markers CA 19/9 and carcinoembryonic antigen (CEA) in colorectal carcinomas: a critical comparison. Int J Biol Markers. 1986 Jan-Apr;1(1):3–8. doi: 10.1177/172460088600100102. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES